GOLPH3 and ductal breast carcinoma in situ: Moreover, FAP-a+GOLPH3− existed in 80.91% (89/110) of DCIS recurrence patients, while only 1.18% (4/339) of DCIS patients without recurrence (4/339) showed FAP-a+GOLPH3+ with statistically significant difference (P < 0.0001).